Insmed Inc.
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE for MAC Lung Disease
Summary
Insmed Incorporated announced positive topline results from its Phase 3b ENCORE study of ARIKAYCE (amikacin liposome inhalation suspension) plus multidrug therapy in patients with a new occurrence of Mycobacterium avium complex (MAC) lung infection. The study met its primary endpoint and all multiplicity-controlled secondary endpoints, demonstrating statistically significant improvements in respiratory symptom score and culture conversion rates. The most common treatment-emergent adverse events were consistent with the known safety profile of ARIKAYCE. Insmed plans to file a supplemental new drug application (sNDA) for ARIKAYCE in the second half of 2026 to support potential label expansion in the U.S. and Japan.
Profitelligence Alerts
Get alerts for INSM
Be first to know when Insmed Inc. files with the SEC.
Filing Categories
Advertisement
About Insmed Inc.
Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.
Official SEC Documents
Advertisement